In episode 2 of the High Potential Start-Ups podcast, we’re joined by CEO of TargTex, João Seixas.  João has a great ambition and an incredible passion for the treatment of brain cancer, and it’s woven through the operations of the business. During this insightful conversation, João details his career, from his journey from academia to business, what he picked up from each step of his career, and how that molded him into the leader that he is today.  João always felt that the world of academics and research were very comfortable and familiar territories, and he moved into industry because he wanted to challenge himself scientifically. That led him to TargTex, a business with a big vision - to help increase the life expectancy of neuro-oncology patients.  In this episode, you’ll find out how to take health from the lab to industry, and get so many more golden nuggets from João.

João Seixas, CEO of TargTex

We’ll learn from life science leaders about the groundbreaking work they’re involved with, and the journey they’ve taken to get to where they are in their career today - what motivates them, how they made it to the C suite in the first place, what it takes to stay there, and where they plan to go next. Guests are positioned as expert minds on compelling missions. The chance to align with personalities and brands on a similar journey is a major draw for talent in today’s busy marketplace. An appearance on the podcast serves as a priceless piece of branding collateral that employers can guarantee represents their message faithfully. Moreover, the podcast affords our guests a platform to draw international attention to the work their organisation is doing, introducing their brand to a global audience of potential investors in the process.

Business

Investing

Careers

Management & Marketing

Business News

Shopping

Entrepreneurship

We’re heading towards a scenario where multidrug-resistant bacteria is set to kill more people a year than cancer. It’s time to prioritise effective antibiotic stewardship; the right antibiotics from the first consultation, and only when needed. 
In this engrossing episode of High Potential Start-Ups, Nick Ross, Co-Founder of https://www.linkedin.com/in/cavenaghhealth/ (Cavenagh Health), is joined by https://www.linkedin.com/in/ndorh/ (Neciah Dorh). 
Neciah is Co-Founder and CEO of FluoretiQ Limited, a Bristol-based start-up addressing the need for rapid tools to detect and identify bacteria in patient samples. 
They discuss the scale of the challenge we’re facing, how FluoretiQ’s solution is different, and what it takes to start and run a business made up of a diverse team.

Neciah Dorh, Co-Founder and CEO of FluoretiQ Limited

We’re heading towards a scenario where multidrug-resistant bacteria is set to kill more people a year than cancer. It’s time to prioritise comprehensive and optimal antibiotic treatment.
In this engrossing episode of High Potential Start-Ups, Nick Ross, Co-Founder of https://www.linkedin.com/in/cavenaghhealth/ (Cavenagh Health), is joined by Neciah Dorh. 
Neciah is Co-Founder and CEO of FluoretiQ Limited, a Bristol-based start-up addressing the need for rapid tools to detect and identify bacteria in patient samples. 
They discuss the scale of the challenge we’re facing, how FluoretiQ’s solution is different, and what it takes to start and run a business made up of a diverse team.  
Get in touch with https://www.linkedin.com/in/ndorh/ (Neciah).
Get in touch with https://www.linkedin.com/in/cavenaghhealth/ (Nick).

Neciah Dorh, Co-Founder & CEO of FluoretiQ Limited

As something that affects as much as 10% of the global population, food allergies are an important topic of discussion in this value-packed episode of High Potential Start-ups. In episode 3, guest speaker Emil Pot, Co-Founder and CEO of Allero Therapeutics, and host Nick Ross, Co-Founder of Cavenagh Health, delve into numerous talking points surrounding everything from food-related immune disorders to running a successful biotech company.  Emil’s career started in law, but his keen interest in science quickly led to biotech becoming the central point of his career. Now, Emil and his team at Allero Therapeutics have developed an innovative solution to treating autoimmune disorders like celiac disease. Get in touch with Emil. Get in Touch with Nick.

Emil Pot, Co-Founder and CEO of Allero Therapeutics

During this inspiring conversation, Shardi reveals the personal story behind starting Tuune, why she hires for mindset over skillset, and why Tuune is fundamentally a learning company.

João Seixas, CEO of TargTex

Download our free app to listen on your phone